Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors

US11236094B2 · kind B2 · utility

Assignee

• CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. · CN

Inventors

• Yikai Wang · Shanghai, CN
• Yang Zhang · San Diego, US
• Zhengxia Chen · Shanghai, CN
• Linlin Chen · Kalispell, US
• Tao Feng · Shanghai, CN
• Rongxin HUANG · Shanghai, CN
• Qiu LI · Shanghai, CN
• Deyao Li · 流花街道, CN
• Jikui SUN · Shanghai, CN
• Yangyang Xu · 安丰镇, CN
• Jie Li · Shanghai, CN
• Jian Li · Shanghai, CN
• Shuhui CHEN · Shanghai, CN

Key dates

• Filing date: Aug 15, 2018
• Grant date: Feb 1, 2022
• Expiry date: Sep 16, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.